**Executive Summary**
This document announces steps taken to ensure a regular supply of medicines at Jan Aushadhi Kendras (JAKs) under the Pradhan Mantri Bhartiya Janaushadhi Yojna. It highlights improvements in the supply chain, quality control measures, and sales figures. The information was provided by the Union Minister of State in the Ministry of Chemicals and Fertilizers on December 5, 2025.
**Key Points / Main Content**
* **Product Basket:**
* The product basket includes 2,110 medicines and 315 surgicals, medical consumables, and devices, covering major therapeutic groups.
* Almost all generic medicines from the National List of Essential Medicines (except lab reagents and vaccines) are included.
* **Supply Chain Improvements:**
* JAKs are incentivized for stocking 200 commonly used medicines since September 2024.
* An IT-enabled supply chain connects a central warehouse, four regional warehouses, and 39 distributors.
* PMBI monitors 400 fast-moving products and forecasts demand for automated procurement.
* **Quality Control Measures:**
* Medicines are sourced only from WHO Good Manufacturing Practices (GMP) certified plants.
* All medicine batches undergo 100% pre-testing before distribution.
* Testing is conducted at labs compliant with Good Laboratory Practices (GLP).
* **Sales and Grievances:**
* Sales increased from ₹1,470 crore in FY 2023-24 to ₹2,022.47 crore in FY 2024-25.
* Grievances can be lodged through the CPGRAMS portal, email, or helpline (1800 180 8080).
* The grievance registration rate is less than 0.0004% with 2,102 total lodged grievances in FY2024-25.
**Impact Analysis**
**JAK Owners**
* **Impact:** Increased incentivisation for stocking commonly used medicines.
* **Action Required:** Maintain stocks of incentivized medicines to be eligible for monthly incentives.
**Consumers/Patients**
* **Impact:** Improved availability and quality of medicines at JAKs.
* **Action Required:** Utilize the grievance redressal mechanisms if necessary.
**Pharmaceuticals and Medical Devices Bureau of India (PMBI)**
* **Impact:** Increased responsibility in monitoring fast-moving products and ensuring GLP compliance.
* **Action Required:** Regularly monitor 400 fast-moving products, forecast demand, and assess labs for GLP compliance.
Key Entities Referenced
Pradhan Mantri Bhartiya Janaushadhi Yojna: A scheme to make quality medicines available at affordable prices through Jan Aushadhi Kendras.
Jan Aushadhi Kendras (JAKs): Pharmacies under the Pradhan Mantri Bhartiya Janaushadhi Yojna where generic medicines are sold.
Pharmaceuticals and Medical Devices Bureau of India (PMBI): The implementing agency for the Pradhan Mantri Bhartiya Janaushadhi Yojna.
Central Drugs Standard Control Organisation (CDSCO): Responsible for approving WHO-GMP certified plants that supply medicines for JAKs after direct inspection.
Ministry of Chemicals and Fertilizers: The ministry under which the Department of Pharmaceuticals operates, overseeing the scheme.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Regular Supply of Medicines at Jan Aushadhi
Kendras (JAKs)
प्रव तथ: 05 DEC 2025 4:21PM by PIB Delhi
The product basket under the Pradhan Mantri Bhartiya Janaushadhi Yojna has 2,110 medicines and 315
surgicals, medical consumables and devices, covering all major therapeutic groups, such as
cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and
nutraceuticals. Almost all generic medicines included in the National List of Essential Medicines, except
lab reagents and vaccines, are part of the product basket.
Number of steps have been taken to ensure effective and regular supply of medicines at Jan Aushadhi
Kendras (JAKs), including the following:
i. Since September 2024, stocking by JAKs of 200 commonly used medicines, consisting of the 100
top-selling medicines in the scheme product basket and 100 fast-selling medicines in the market, has
been incentivised, under which JAK owners are eligible for monthly incentive based on the stocks
that they maintain of these medicines.
ii. An end-to-end information-technology-enabled supply chain system is in place to connect a robust
supply chain system consisting of one central warehouse, four regional warehouses and a growing
network of distributors across the country, currently numbering 39.
iii. In addition, with a view to ensure availability of commonly used products, 400 fast-moving
products are monitored regularly by the scheme implementing agency Pharmaceuticals and Medical
Devices Bureau of India (PMBI} and demand for the same is forecasted on an ongoing basis.
Further, steps have been taken to digitise the forecasting method to augment the procurement
process through automation.
As a result, the sale of medicines from JAKs has increased from maximum retail price value totalling
₹1,470 crore in the financial year (FY) 2023-24 to ₹2,022.47 crore in FY2024-25.
Anyone, including experts, consumers and doctors, may lodge their grievances regarding JAKs, including
in respect of quality of medicines made available through them, using the Centralised Public Grievance
Redress and Monitoring System (CPGRAMS) portal of the Government of India or by emailing the same
to complaints@janaushadhi.gov.in or calling the scheme helpline number 1800 180 8080. While about 15
lakh consumers purchase Janaushadhi daily across the country, the number of grievances lodged during
the whole year in FY2024-25 was 2,102, which translates into a grievance registration rate of less than
0.0004%.
With a view to ensure quality of medicines available at JAKs so that health of patients is not
compromised, concrete mechanisms have been put in place to ensure continuous inspection, testing and
standardisation, including the following:i. Supply only from WHO Good Manufacturing Practices (GMP) certified plants: Only plants that are
certified as WHO-GMP compliant by the Central Drugs Standard Control Organisation (CDSCO)
after direct inspection are eligible for supply.
ii. Distribution only after 100% pre-testing of all medicine batches: Samples are drawn from 100% of
batches supplied at PMBI’s warehouses for testing anonymously, and medicines are dispatched for
supply to JAKs only after the quality test is passed.
iii. Testing only at labs compliant with Good Laboratory Practices (GLP): Samples are tested only at
labs accredited and periodically inspected by the National Accreditation Board for Testing and
Calibration Laboratories (NABL) and, in addition, assessed by PMBI for GLP compliance.
This information was given by Union Minister of State in the Ministry of Chemicals and Fertilizers, Smt.
Anupriya Patel, in a written reply in Lok Sabha today.
******
PC/GS/SG
(रलीज़ आईडी: 2199427) आगंतुक पटल : 302
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही